Article in Circulation research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
3 authors.
Sakthivel SadayappanDivision of Cardiovascular Health and Disease, Department of Internal Medicine, Heart, Lung and Vascular Institute, University of Cincinnati, OH (S.S.).
Jil C TardiffDepartment of Biomedical Engineering and Medicine, University of Arizona, Tucson, AZ (J.C.T.).
Loren E WoldCollege of Nursing (L.E.W.).
Funding
Integrative Approach to Divergent Remodeling in Thin Filament CardiomyopathiesR01HL075619 · NHLBI · UNIVERSITY OF ARIZONA · PI TARDIFF, JIL C · 2004 to 2025
$8.6M
The interaction of myosin and the thin filament: how mutations cause allosteric dysfunction and their connection to genetic cardiomyopathyR01HL107046 · NHLBI · UNIVERSITY OF ARIZONA · PI SCHWARTZ, STEVEN D, TARDIFF, JIL C · 2011 to 2023
$6.0M
Fast myosin binding protein-C and cardiac contractility in heart failureR01HL105826 · NHLBI · UNIVERSITY OF CINCINNATI · PI SADAYAPPAN, SAKTHIVEL · 2011 to 2025
$4.5M
Mechanisms of exposure-induced tissue functional and pathological changes in a mouse model of Alzheimer's DiseaseR01AG057046 · NIA · OHIO STATE UNIVERSITY · PI COMBS, COLIN K, DEL MONTE, FEDERICA · 2017 to 2021
$4.0M
Skeletal Myosin-Binding Protein C (MyBP-C): Molecular Structure and FunctionR01AR067279 · NIAMS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI CRAIG, ROGER W, WARSHAW, DAVID M · 2015 to 2019
$2.3M
Defining the Impact of E-Cigarettes on Cardiac PathophysiologyR01HL139348 · NHLBI · OHIO STATE UNIVERSITY · PI WOLD, LOREN EUGENE · 2017 to 2020
$1.9M
A New Paradigm to Incorporate Protein Dynamics into Targeted Small Molecule Design for Sarcomeric Cardiomyopathies: A Proof of Concept for Thin Filament TherapeuticsR01HL137375 · NHLBI · UNIVERSITY OF ARIZONA · PI SCHWARTZ, STEVEN D, TARDIFF, JIL C · 2018 to 2021
$1.9M
Slow myosin binding protein-C in skeletal muscle physiologyR01AR078001 · NIAMS · UNIVERSITY OF CINCINNATI · PI SADAYAPPAN, SAKTHIVEL · 2020 to 2023
$1.8M
Synergistic effects of obesity and air pollution on cardiac functionR01ES019923 · NIEHS · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI WOLD, LOREN EUGENE · 2011 to 2015
$1.8M
IGF-2R is a new therapeutic target for cardiac ischemia-reperfusion injuryR01HL143490 · NHLBI · UNIVERSITY OF CINCINNATI · PI WANG, YIGANG · 2019 to 2022
$1.6M
Molecular mechanism of hypertrophic cardiomyopathy in populations of South Asian descendantsR01HL130356 · NHLBI · UNIVERSITY OF CINCINNATI · PI SADAYAPPAN, SAKTHIVEL · 2016 to 2019
$1.6M
Mechanisms Underlying Preterm Birth in Minority WomenR01NR010552 · NINR · BOSTON COLLEGE · PI GENNARO, SUSAN · 2009 to 2012
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Basic Cardiovascular Sciences Scientific Sessions 2020: Emerging Opportunities in Cardiovascular Diseases. · full record | OpenQuestion